Related references
Note: Only part of the references are listed.Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance
Dong Jiang et al.
LIVER INTERNATIONAL (2020)
Evaluation of drug resistance mutations in patients with chronic hepatitis B
Sema Alacam et al.
FOLIA MICROBIOLOGICA (2019)
Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial
Young-Suk Lim et al.
JOURNAL OF HEPATOLOGY (2019)
Monotherapy With Tenofovir Disoproxil Fumarate for Multiple Drug-Resistant Chronic Hepatitis B: 3-Year Trial
Young-Suk Lim et al.
HEPATOLOGY (2017)
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
JOURNAL OF HEPATOLOGY (2017)
Comparison of the Efficacy of Tenofovir Versus Tenofovir plus Entecavir in the Treatment of Chronic Hepatitis B in Patients With Poor Efficacy of Entecavir: A Systematic Review and Meta-analysis
Jun Chen et al.
CLINICAL THERAPEUTICS (2017)
Tenofovir alafenamide demonstrates broad cross-genotype activity 'against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro
Yang Liu et al.
ANTIVIRAL RESEARCH (2017)
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial
Young-Suk Lim et al.
GUT (2016)
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
S. K. Sarin et al.
HEPATOLOGY INTERNATIONAL (2016)
Overview of hepatitis B viral replication and genetic variability
Shuping Tong et al.
JOURNAL OF HEPATOLOGY (2016)
Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones
Eisuke Murakami et al.
JOURNAL OF INFECTION (2016)
Requirements for global elimination of hepatitis B: a modelling study
Shevanthi Nayagam et al.
LANCET INFECTIOUS DISEASES (2016)
Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies
Hyoung Su Kim et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir
L. Lu et al.
JOURNAL OF VIRAL HEPATITIS (2015)
Efficacy of Entecavir-Tenofovir Combination Therapy for Chronic Hepatitis B Patients with Multidrug-Resistant Strains
Yun Bin Lee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
The Global Burden of Liver Disease: The Major Impact of China
Fu-Sheng Wang et al.
HEPATOLOGY (2014)
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice
R. Salpini et al.
JOURNAL OF MEDICAL VIROLOGY (2013)
Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance
Fabien Zoulim et al.
LIVER INTERNATIONAL (2013)
Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities
Leal C. Herlitz et al.
KIDNEY INTERNATIONAL (2010)
Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present
Daniel J. Tenney et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation
SK Fung et al.
JOURNAL OF HEPATOLOGY (2005)
Share Paper
